LSIPR 50 2018: Padmanabh Bhatt

Name: Padmanabh Bhatt

Organisation: Supernus Pharmaceuticals

Position: Senior Vice President, IP and Chief Scientific Officer

With more than three decades of experience in the pharmaceutical industry, Padmanabh Bhatt has led an admirable career in the life sciences field.

As senior vice president, IP and chief scientific officer at Supernus Pharmaceuticals, Bhatt was responsible for the product development of Supernus’ two commercial products: Oxtellar XR (oxcarbazepine) and Trokendi XR (topiramate). Furthermore, he is accountable for two of the company’s three pipeline products: SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride).

In his position at Supernus, Bhatt leads the worldwide prosecution of patents, trademarks and copyright.

The company, which specialises in drugs treating diseases of the nervous system such as epilepsy, ADHD and depression, reported a one-year revenue growth of 45.8% for December 22, 2017, with a one-year net income growth of 554.24% and one-year earnings per share growth of 528.6%.

Analysts are estimating that sales for 2018 will be up 32%, with a 50% increase in earnings per share for the
year.

Before taking on his role at Supernus in March 2012, from 2005 Bhatt served as the company’s vice president of pharmaceutical sciences. He has also held positions at Shire Laboratories and Point Biomedical Corporation.

Bhatt has bachelor’s and master’s degrees in pharmacy from the University of Bombay in India, and a PhD in pharmaceutical chemistry from the University of Kansas.